FI943363A - Menetelmä uusien terapeuttisesti käyttökelpoisten /1,4/oksatsino/3,4-a//2/bentsatsepiinijohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien terapeuttisesti käyttökelpoisten /1,4/oksatsino/3,4-a//2/bentsatsepiinijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI943363A
FI943363A FI943363A FI943363A FI943363A FI 943363 A FI943363 A FI 943363A FI 943363 A FI943363 A FI 943363A FI 943363 A FI943363 A FI 943363A FI 943363 A FI943363 A FI 943363A
Authority
FI
Finland
Prior art keywords
oxazino
preparation
therapeutically useful
benzazepine derivatives
novel therapeutically
Prior art date
Application number
FI943363A
Other languages
English (en)
Swedish (sv)
Other versions
FI96691C (fi
FI943363A0 (fi
FI96691B (fi
Inventor
Gary Alan Flynn
Philippe Bey
Alan M Warshawsky
Douglas Wade Beight
Shujaath Mehdi
Eugene Lewis Giroux
Timothy Paul Burkholder
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI943363A0 publication Critical patent/FI943363A0/fi
Publication of FI943363A publication Critical patent/FI943363A/fi
Application granted granted Critical
Publication of FI96691B publication Critical patent/FI96691B/fi
Publication of FI96691C publication Critical patent/FI96691C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
FI943363A 1990-10-18 1994-07-14 Menetelmä uusien terapeuttisesti käyttökelpoisten /1,4/oksatsino/3,4-a//2/bentsatsepiinijohdannaisten valmistamiseksi FI96691C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60005290A 1990-10-18 1990-10-18
US60005290 1990-10-18
US73549691A 1991-07-25 1991-07-25
US73549691 1991-07-25

Publications (4)

Publication Number Publication Date
FI943363A0 FI943363A0 (fi) 1994-07-14
FI943363A true FI943363A (fi) 1994-07-14
FI96691B FI96691B (fi) 1996-04-30
FI96691C FI96691C (fi) 1996-08-12

Family

ID=27083513

Family Applications (2)

Application Number Title Priority Date Filing Date
FI914905A FI95255C (fi) 1990-10-18 1991-10-17 Menetelmä uusien terapeuttisesti käyttökelpoisten merkaptoasetyyliamidopyrrolo- ja -pyridobentsatsepiinijohdannaisten valmistamiseksi
FI943363A FI96691C (fi) 1990-10-18 1994-07-14 Menetelmä uusien terapeuttisesti käyttökelpoisten /1,4/oksatsino/3,4-a//2/bentsatsepiinijohdannaisten valmistamiseksi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI914905A FI95255C (fi) 1990-10-18 1991-10-17 Menetelmä uusien terapeuttisesti käyttökelpoisten merkaptoasetyyliamidopyrrolo- ja -pyridobentsatsepiinijohdannaisten valmistamiseksi

Country Status (18)

Country Link
EP (1) EP0481522B1 (fi)
JP (1) JP3181335B2 (fi)
KR (1) KR100372491B1 (fi)
CN (2) CN1036590C (fi)
AT (1) ATE161536T1 (fi)
AU (1) AU642535B2 (fi)
CA (1) CA2053340C (fi)
DE (1) DE69128516T2 (fi)
DK (1) DK0481522T3 (fi)
ES (1) ES2114870T3 (fi)
FI (2) FI95255C (fi)
GR (1) GR3026222T3 (fi)
HU (1) HU210008B (fi)
IE (1) IE913648A1 (fi)
IL (1) IL99769A (fi)
NO (1) NO180718C (fi)
NZ (1) NZ240230A (fi)
PT (1) PT99267B (fi)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
NZ241023A (en) * 1990-12-21 1994-10-26 Merrell Dow Pharma Condensed benzazepine derivatives and pharmaceutical compositions
CA2078759C (en) * 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
US5455242A (en) * 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
DE69220744T2 (de) * 1991-09-27 1997-11-13 Merrell Pharma Inc 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
DK0625987T3 (da) * 1992-02-14 1999-01-11 Merrell Pharma Inc Aminoacetylmercaptoacetylamid-derivater, der kan anvendes som inhibitorer af enkephalinase og ACE
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
ATE182892T1 (de) * 1992-05-15 1999-08-15 Merrell Pharma Inc Mercaptoacetylamide von pyridazo(1,2-a>(1,2>- diazepin -derivaten als eukephalinase und ace- inhibitoren
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5238932A (en) * 1992-05-20 1993-08-24 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5298492A (en) * 1992-08-04 1994-03-29 Schering Corporation Diamino acid derivatives as antihypertensives
DK0656001T3 (da) * 1992-08-24 2000-04-03 Merrell Pharma Inc Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
DE69329701T2 (de) * 1992-10-30 2001-05-10 Merrell Pharma Inc Mercaptoacetylamid substituiertes bizyclisches laktam zur verwendung als enkephalinase und ace-hemmer
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
GB9310075D0 (en) * 1993-05-17 1993-06-30 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JP3563738B2 (ja) * 1993-06-11 2004-09-08 エーザイ株式会社 アミノ酸誘導体
AU680512B2 (en) * 1993-06-11 1997-07-31 Eisai Co. Ltd. Amino acid derivative
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
JPH09500113A (ja) * 1993-06-30 1997-01-07 チバ−ガイギー アクチェンゲゼルシャフト エンケファリナーゼ及びａｃｅのインヒビターとして有用な抗高血圧性三環式アゼピン誘導体
ES2076096B1 (es) * 1993-07-14 1996-03-16 Squibb & Sons Inc Compuestos inhibidores de la enzima convertidora de angiotensinas y dela endopeptidasa neutra, y metodos para prepararlos.
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
DK0750631T3 (da) * 1994-02-14 2000-10-23 Merrell Pharma Inc Mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[c]azepin-3-ondisulfidderivater som enkephalinase- og ACE-inhibitorer
ES2131806T3 (es) * 1994-02-14 1999-08-01 Merrell Pharma Inc Nuevos derivados de disulfuro de mercaptoacetilamida utiles como inhibidores de encefalinasa y ace.
KR100348949B1 (ko) * 1994-02-14 2003-01-24 메렐 파마슈티칼스 인크. 엔케팔리나제의억제제로서유용한신규의인단-2-머캅토아세틸아미드디술파이드유도체
HUT76479A (en) * 1994-02-14 1997-09-29 Merrell Pharma Inc Novel fused benzazepinone derivatives, process for preparation thereof and pharmaceutical composition containing them
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
DE69514912T2 (de) * 1994-03-24 2000-10-05 Merrell Pharma Inc Hypocholesterolemische, antiatherosklerotische und hypotriglyceridemische verwendung von aminoacetylmercapto derivaten
DE69531489T2 (de) * 1994-03-24 2004-04-08 Merrell Pharmaceuticals Inc., Cincinnati Cholesterin senkende mercaptoacetylamiddisulfidderivate
US5616775A (en) * 1994-05-05 1997-04-01 Bristol-Myers Squibb Co. Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring
US5641880A (en) * 1994-12-21 1997-06-24 Hoechst Marion Roussel, Inc. Processes for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
CN1241924C (zh) * 1994-12-21 2006-02-15 阿温蒂斯药物公司 制备脑啡肽酶与血管紧张素转化酶抑制剂中间体的新方法及其中间体
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
CA2332608C (en) 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
TR200200515T2 (tr) 1999-08-30 2002-11-21 Aventis Pharma Deutschland Gmbh Renin-anjiyotensin sistem önleyicilerinin kardiyovasküler vakaların engellenmesinde kullanılması.
EE05272B1 (et) * 2001-04-12 2010-02-15 Aventis Pharma Deutschland Gmbh Merkaptoatsetlamiidi derivaadid, nende valmistamismeetod ja kasutamine
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7009047B2 (en) 2002-03-19 2006-03-07 Sanofi-Aventis Deutschland Gmbh Ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenylpropanoate], processes for its preparation and its use
DE10212198A1 (de) * 2002-03-19 2003-10-02 Aventis Pharma Gmbh Ethan-1-diaminium-bis(2R)-2-brom-3-phenylpropanoat), Verfahren zu dessen Herstellung und dessen Verwendung
DE10229180A1 (de) * 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MXPA06012932A (es) 2004-05-07 2007-01-26 Janssen Pharmaceutica Nv Derivados de pirrolidin-2-ona y piperidin-2-ona como inhibidores de 11-beta hidroxiesteroide deshidrogenasa.
FR2872164B1 (fr) * 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2008057857A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009158380A1 (en) 2008-06-24 2009-12-30 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010059618A1 (en) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
CA1337654C (en) * 1986-06-13 1995-11-28 Gary A. Flynn Fused tricyclic lactams as antihypertensive agents
US4824832A (en) * 1987-12-30 1989-04-25 Merrell Dow Pharmaceuticals Inc. Sulfhydryl containing tricyclic lactams and their pharmacological methods of use

Also Published As

Publication number Publication date
JPH04282382A (ja) 1992-10-07
FI96691C (fi) 1996-08-12
GR3026222T3 (en) 1998-05-29
IL99769A (en) 1998-12-27
AU642535B2 (en) 1993-10-21
ATE161536T1 (de) 1998-01-15
NO914092D0 (no) 1991-10-17
NO180718B (no) 1997-02-24
EP0481522B1 (en) 1997-12-29
CA2053340C (en) 2002-04-02
NO180718C (no) 1997-06-04
IL99769A0 (en) 1992-08-18
DE69128516T2 (de) 1998-07-23
CN1058013C (zh) 2000-11-01
HU913282D0 (en) 1992-01-28
DE69128516D1 (de) 1998-02-05
AU8581991A (en) 1992-04-30
FI943363A0 (fi) 1994-07-14
HUT63419A (en) 1993-08-30
DK0481522T3 (da) 1998-03-09
PT99267A (pt) 1992-08-31
ES2114870T3 (es) 1998-06-16
CA2053340A1 (en) 1992-04-19
EP0481522A1 (en) 1992-04-22
KR920008040A (ko) 1992-05-27
NZ240230A (en) 1993-01-27
FI96691B (fi) 1996-04-30
HU210008B (en) 1995-01-30
JP3181335B2 (ja) 2001-07-03
CN1166490A (zh) 1997-12-03
IE913648A1 (en) 1992-04-22
FI95255C (fi) 1996-01-10
PT99267B (pt) 1999-04-30
FI95255B (fi) 1995-09-29
FI914905A (fi) 1992-04-19
CN1061971A (zh) 1992-06-17
FI914905A0 (fi) 1991-10-17
NO914092L (no) 1992-04-21
KR100372491B1 (ko) 2003-05-27
CN1036590C (zh) 1997-12-03

Similar Documents

Publication Publication Date Title
FI943363A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten /1,4/oksatsino/3,4-a//2/bentsatsepiinijohdannaisten valmistamiseksi
FI101302B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 7-(2-karboksialkyyli-2-okso)metyyliamino-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino[2,1-a]bentsatsepiini- ja -[1,4]oksatsino- ja -tiatsino[3,4-a][2]bentsatsepiini-4-karboksyylihappojohdannaisten valmistamiseksi
FI101303B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamino-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino[2,1-a][2]bentsatsepiini- ja -oksatsino- ja -tiatsino[3,4-a][2]bentsatsepiini-4-karboksyylihappojohdannaisten valmistamiseksi
FI890282A (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI906438A (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten A-nor-steroidi-3-karboksyylihappojohdannaisten valmistamiseksi
FI880467A (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 3,4-dihydro-2H-bentsopyraanien valmistamiseksi
FI93215C (fi) Menetelmä terapeuttisesti käyttökelpoisten aminoalkoksifenyylijohdannaisten valmistamiseksi
FI873350A (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi
FI98461B (fi) Menetelmä terapeuttisesti käyttökelpoisten yhdisteiden valmistamiseksi
HUT51295A (en) Process for producing peptidalcohol derivatives of anticoagulant activity
FI911701A (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-substituoitujen alkyyli-3-karboksikarbapeneemien valmistamiseksi
FI92188C (fi) Menetelmä terapeuttisesti käyttökelpoisten fenoksialkyylipyrokatekolijohdannaisten valmistamiseksi
FI953361A0 (fi) Menetelmä substituoitujen indolonijohdannaisten valmistamiseksi
FI893250A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 1,4-diatsepiinijohdannaisten valmistamiseksi
FI893121A (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
IT9019111A0 (it) Procedimento perfezionato per la produzione di vanadio areni
PT88578A (pt) Process for the manufacture of 2,6-methanopyrrolo-3-benzazocines of intermediates useful for their manufacture and of pharmaceutical compositions containing them
FI944128A0 (fi) Menetelmä N-(2-pyrimidyyli)piperatsinyyli-butyyli-imidien valmistamiseksi
FI942927A (fi) Menetelmä terapeuttisesti käyttökelpoisten tetrahydronaftaleenijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: AVENTIS INC.

Free format text: AVENTIS INC.

PC Transfer of assignment of patent

Owner name: AVENTISUB II INC.

Free format text: AVENTISUB II INC.

MA Patent expired